;PMID: 10499618
;source_file_554.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..37] = [t:0..37]
;1)sentence:[e:42..159] = [t:42..159]
;2)section:[e:163..268] = [t:163..268]
;3)section:[e:272..391] = [t:272..391]
;4)sentence:[e:395..515] = [t:395..515]
;5)sentence:[e:516..635] = [t:516..635]
;6)sentence:[e:636..938] = [t:636..938]
;7)sentence:[e:939..1056] = [t:939..1056]
;8)sentence:[e:1057..1182] = [t:1057..1182]
;9)sentence:[e:1183..1399] = [t:1183..1399]
;10)sentence:[e:1400..1540] = [t:1400..1540]
;11)sentence:[e:1541..1653] = [t:1541..1653]
;12)sentence:[e:1654..1966] = [t:1654..1966]
;13)sentence:[e:1967..2128] = [t:1967..2128]
;14)sentence:[e:2129..2348] = [t:2129..2348]
;15)sentence:[e:2349..2628] = [t:2349..2628]
;16)section:[e:2632..2650] = [t:2632..2650]
;17)section:[e:2652..2666] = [t:2652..2666]
;18)section:[e:2668..2685] = [t:2668..2685]
;19)section:[e:2689..2734] = [t:2689..2734]

;section 0 Span:0..37
;Clin Cancer Res  1999 Sep;5(9):2450-4
(SEC
  (FRAG (NNP:[0..4] Clin) (NNP:[5..11] Cancer) (NNP:[12..15] Res)
        (CD:[17..21] 1999) (.:[22..28] Sep;5-LRB-) (CD:[28..29] 9)
        (-RRB-:[29..30] -RRB-) (CD:[30..35] :2450) (::[35..36] -)
        (CD:[36..37] 4)))

;sentence 1 Span:42..159
;Molecular detection of neoplastic cells in lymph nodes of metastatic
;colorectal  cancer patients predicts recurrence.
;[65..96]:malignancy:"neoplastic cells in lymph nodes"
;[100..129]:malignancy:"metastatic colorectal  cancer"
(SENT
  (S-HLN
    (NP-SBJ
      (NP (JJ:[42..51] Molecular) (NN:[52..61] detection))
      (PP (IN:[62..64] of)
        (NP (JJ:[65..75] neoplastic) (NNS:[76..81] cells)))
      (PP-LOC (IN:[82..84] in)
        (NP
          (NP (NN:[85..90] lymph) (NNS:[91..96] nodes))
          (PP (IN:[97..99] of)
            (NP
              (NML (JJ:[100..110] metastatic) (JJ:[111..121] colorectal)
                   (NN:[123..129] cancer))
              (NNS:[130..138] patients))))))
    (VP (VBZ:[139..147] predicts)
      (NP (NN:[148..158] recurrence)))
    (.:[158..159] .)))

;section 2 Span:163..268
;Sanchez-Cespedes M, Esteller M, Hibi K, Cope FO, Westra WH, Piantadosi S,
;Herman  JG, Jen J, Sidransky D.
(SEC
  (FRAG (NNP:[163..170] Sanchez) (::[170..171] -) (NNP:[171..179] Cespedes)
        (NNP:[180..182] M,) (NNP:[183..191] Esteller) (NNP:[192..194] M,)
        (NNP:[195..199] Hibi) (NNP:[200..201] K) (,:[201..202] ,)
        (NNP:[203..207] Cope) (NNP:[208..210] FO) (,:[210..211] ,)
        (NNP:[212..218] Westra) (NNP:[219..221] WH) (,:[221..222] ,)
        (NNP:[223..233] Piantadosi) (NNP:[234..236] S,) (NNP:[237..243] Herman)
        (NNP:[245..247] JG) (,:[247..248] ,) (NNP:[249..252] Jen)
        (NNP:[253..255] J,) (NNP:[256..265] Sidransky) (NNP:[266..268] D.)))

;section 3 Span:272..391
;Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins
;Oncology  Center, Baltimore, Maryland 21205, USA.
(SEC
  (FRAG (NNP:[272..282] Department) (IN:[283..285] of)
        (NNP:[286..300] Otolaryngology) (::[300..301] -) (NNP:[301..305] Head)
        (CC:[306..309] and) (NNP:[310..314] Neck) (NNP:[315..322] Surgery)
        (,:[322..323] ,) (DT:[324..327] The) (NNP:[328..333] Johns)
        (NNP:[334..341] Hopkins) (NNP:[342..350] Oncology)
        (NNP:[352..358] Center) (,:[358..359] ,) (NNP:[360..369] Baltimore)
        (,:[369..370] ,) (NNP:[371..379] Maryland) (VBZ:[380..385] 21205)
        (NNP:[385..386] ,) (NNP:[387..390] USA) (.:[390..391] .)))

;sentence 4 Span:395..515
;Disseminated disease, especially to the liver, constitutes the major risk of 
;recurrence for colorectal cancer patients.
;[488..505]:malignancy:"colorectal cancer"
(SENT
  (S
    (NP-SBJ (VBN:[395..407] Disseminated) (NN:[408..415] disease))
    (,:[415..416] ,)
    (PP
      (ADVP (RB:[417..427] especially))
      (TO:[428..430] to)
      (NP (DT:[431..434] the) (NN:[435..440] liver)))
    (,:[440..441] ,)
    (VP (VBZ:[442..453] constitutes)
      (NP
        (NP (DT:[454..457] the) (JJ:[458..463] major) (NN:[464..468] risk))
        (PP (IN:[469..471] of)
          (NP (NN:[473..483] recurrence)))
        (PP (IN:[484..487] for)
          (NP
            (NML (JJ:[488..498] colorectal) (NN:[499..505] cancer))
            (NNS:[506..514] patients)))))
    (.:[514..515] .)))

;sentence 5 Span:516..635
;However, successful resection can  still be achieved in 25-35% of colorectal
;cancer patients with isolated  metastases.
;[582..599]:malignancy:"colorectal cancer"
;[624..634]:malignancy:"metastases"
(SENT
  (S
    (ADVP (RB:[516..523] However))
    (,:[523..524] ,)
    (NP-SBJ-1 (JJ:[525..535] successful) (NN:[536..545] resection))
    (VP (MD:[546..549] can)
      (ADVP (RB:[551..556] still))
      (VP (VB:[557..559] be)
        (VP (VBN:[560..568] achieved)
          (NP-1 (-NONE-:[568..568] *))
          (PP (IN:[569..571] in)
            (NP
              (NP
                (QP (CD:[572..574] 25) (HYPH:[574..575] -) (CD:[575..577] 35))
                (NN:[577..578] %))
              (PP (IN:[579..581] of)
                (NP
                  (NP
                     (JJ:[582..592] colorectal) (NN:[593..599] cancer)
                    (NNS:[600..608] patients))
                  (PP (IN:[609..613] with)
                    (NP (VBN:[614..622] isolated) (NNS:[624..634] metastases))))))))))
    (.:[634..635] .)))

;sentence 6 Span:636..938
;To evaluate the clinical value of occult micrometastatic disease  detection
;in lymph nodes, we tested genetic (K-ras and p53 gene mutations) and 
;epigenetic (p16 promoter hypermethylation) molecular markers in the
;perihepatic  lymph nodes from colorectal cancer patients with isolated liver
;metastases.
;[747..752]:gene-rna:"K-ras"
;[757..760]:gene-rna:"p53"
;[794..797]:gene-rna:"p16"
;[880..897]:malignancy:"colorectal cancer"
;[921..937]:malignancy:"liver metastases"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[636..636] *))
      (VP (TO:[636..638] To)
        (VP (VB:[639..647] evaluate)
          (NP
            (NP (DT:[648..651] the) (JJ:[652..660] clinical)
                (NN:[661..666] value))
            (PP (IN:[667..669] of)
              (NP (JJ:[670..676] occult) (JJ:[677..692] micrometastatic)
                  (NN:[693..700] disease) (NN:[702..711] detection))))
          (PP-LOC (IN:[712..714] in)
            (NP (NN:[715..720] lymph) (NNS:[721..726] nodes))))))
    (,:[726..727] ,)
    (NP-SBJ (PRP:[728..730] we))
    (VP (VBD:[731..737] tested)
      (NP
        (NP (JJ:[738..745] genetic)
          (PRN (-LRB-:[746..747] -LRB-)
            (NP
              (NP (NN:[747..752] K-ras)
                (NML-2 (-NONE-:[752..752] *P*)))
              (CC:[753..756] and)
              (NP (NN:[757..760] p53)
                (NML-2 (NN:[761..765] gene) (NNS:[766..775] mutations))))
            (-RRB-:[775..776] -RRB-))
          (NML-1 (-NONE-:[776..776] *P*)))
        (CC:[777..780] and)
        (NP (JJ:[782..792] epigenetic)
          (PRN (-LRB-:[793..794] -LRB-)
            (NP (NN:[794..797] p16) (NN:[798..806] promoter)
                (NN:[807..823] hypermethylation))
            (-RRB-:[823..824] -RRB-))
          (NML-1 (JJ:[825..834] molecular) (NNS:[835..842] markers))))
      (PP-LOC (IN:[843..845] in)
        (NP
          (NP (DT:[846..849] the) (JJ:[850..861] perihepatic)
              (NN:[863..868] lymph) (NNS:[869..874] nodes))
          (PP (IN:[875..879] from)
            (NP
              (NP
                (NML (JJ:[880..890] colorectal) (NN:[891..897] cancer))
                (NNS:[898..906] patients))
              (PP (IN:[907..911] with)
                (NP (VBN:[912..920] isolated)
                   (NN:[921..926] liver) (NNS:[927..937] metastases))))))))
    (.:[937..938] .)))

;sentence 7 Span:939..1056
;DNA  was extracted from 21 paraffin-embedded liver metastases and 80 lymph
;nodes from  21 colorectal cancer patients.
;[984..1000]:malignancy:"liver metastases"
;[1029..1046]:malignancy:"colorectal cancer"
(SENT
  (S
    (NP-SBJ-1 (NN:[939..942] DNA))
    (VP (VBD:[944..947] was)
      (VP (VBN:[948..957] extracted)
        (NP-1 (-NONE-:[957..957] *))
        (PP (IN:[958..962] from)
          (NP
            (NP
              (NP (CD:[963..965] 21)
                (ADJP (NN:[966..974] paraffin) (HYPH:[974..975] -)
                      (VBN:[975..983] embedded))
                 (NN:[984..989] liver) (NNS:[990..1000] metastases))
              (CC:[1001..1004] and)
              (NP (CD:[1005..1007] 80) (NN:[1008..1013] lymph)
                  (NNS:[1014..1019] nodes)))
            (PP (IN:[1020..1024] from)
              (NP (CD:[1026..1028] 21)
                (NML (JJ:[1029..1039] colorectal) (NN:[1040..1046] cancer))
                (NNS:[1047..1055] patients)))))))
    (.:[1055..1056] .)))

;sentence 8 Span:1057..1182
;K-ras and p53 gene mutations were identified in  DNA from liver metastases by
;PCR amplification followed by cycle sequencing.
;[1057..1062]:gene-rna:"K-ras"
;[1067..1070]:gene-rna:"p53"
;[1115..1131]:malignancy:"liver metastases"
(SENT
  (S
    (NP-SBJ-2
      (NP (NN:[1057..1062] K-ras)
        (NML-1 (-NONE-:[1062..1062] *P*)))
      (CC:[1063..1066] and)
      (NP (NN:[1067..1070] p53)
        (NML-1 (NN:[1071..1075] gene) (NNS:[1076..1085] mutations))))
    (VP (VBD:[1086..1090] were)
      (VP (VBN:[1091..1101] identified)
        (NP-2 (-NONE-:[1101..1101] *))
        (PP (IN:[1102..1104] in)
          (NP
            (NP (NN:[1106..1109] DNA))
            (PP (IN:[1110..1114] from)
              (NP (NN:[1115..1120] liver) (NNS:[1121..1131] metastases)))))
        (PP (IN:[1132..1134] by)
          (NP
            (NP (NN:[1135..1138] PCR) (NN:[1139..1152] amplification))
            (VP (VBN:[1153..1161] followed)
              (NP (-NONE-:[1161..1161] *))
              (PP (IN:[1162..1164] by)
                (NP-LGS (NN:[1165..1170] cycle) (NN:[1171..1181] sequencing))))))))
    (.:[1181..1182] .)))

;sentence 9 Span:1183..1399
;A  sensitive oligonucleotide-mediated mismatch ligation assay was used to
;search  for the presence of K-ras and p53 mutations to detect occult disease
;in 68 lymph  nodes from tumors positive for these gene mutations.
;[1285..1290]:gene-rna:"K-ras"
;[1295..1298]:gene-rna:"p53"
;[1358..1364]:malignancy:"tumors"
;[1384..1388]:malignancy:"gene"
(SENT
  (S
    (NP-SBJ-2 (DT:[1183..1184] A) (JJ:[1186..1195] sensitive)
      (ADJP (NN:[1196..1211] oligonucleotide) (HYPH:[1211..1212] -)
            (VBN:[1212..1220] mediated))
      (NN:[1221..1229] mismatch) (NN:[1230..1238] ligation)
       (NN:[1239..1244] assay))
    (VP (VBD:[1245..1248] was)
      (VP (VBN:[1249..1253] used)
        (NP-2 (-NONE-:[1253..1253] *))
        (S-ADV
          (NP-SBJ (-NONE-:[1253..1253] *))
          (VP (TO:[1254..1256] to)
            (VP (VB:[1257..1263] search)
              (PP (IN:[1265..1268] for)
                (NP
                  (NP (DT:[1269..1272] the) (NN:[1273..1281] presence))
                  (PP (IN:[1282..1284] of)
                    (NP
                      (NP (NN:[1285..1290] K-ras)
                        (NML-1 (-NONE-:[1290..1290] *P*)))
                      (CC:[1291..1294] and)
                      (NP (NN:[1295..1298] p53)
                        (NML-1 (NNS:[1299..1308] mutations))))))))))
        (S-ADV
          (NP-SBJ (-NONE-:[1308..1308] *))
          (VP (TO:[1309..1311] to)
            (VP (VB:[1312..1318] detect)
              (NP (JJ:[1319..1325] occult) (NN:[1326..1333] disease))
              (PP (IN:[1334..1336] in)
                (NP
                  (NP (CD:[1337..1339] 68) (NN:[1340..1345] lymph)
                      (NNS:[1347..1352] nodes))
                  (PP (IN:[1353..1357] from)
                    (NP
                      (NP (NNS:[1358..1364] tumors))
                      (ADJP (JJ:[1365..1373] positive)
                        (PP (IN:[1374..1377] for)
                          (NP (DT:[1378..1383] these) (NN:[1384..1388] gene)
                              (NNS:[1389..1398] mutations)))))))))))))
    (.:[1398..1399] .)))

;sentence 10 Span:1400..1540
;Promoter hypermethylation  at the p16 tumor suppressor gene was examined in
;both liver lesions and lymph  nodes by methylation-specific PCR.
;[1434..1437]:gene-rna:"p16"
;[1481..1494]:malignancy:"liver lesions"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[1400..1408] Promoter) (NN:[1409..1425] hypermethylation))
      (PP (IN:[1427..1429] at)
        (NP (DT:[1430..1433] the) (NN:[1434..1437] p16)
          (NML (NN:[1438..1443] tumor) (NN:[1444..1454] suppressor))
          (NN:[1455..1459] gene))))
    (VP (VBD:[1460..1463] was)
      (VP (VBN:[1464..1472] examined)
        (NP-1 (-NONE-:[1472..1472] *))
        (PP-LOC (IN:[1473..1475] in)
          (NP (CC:[1476..1480] both)
            (NP (NN:[1481..1486] liver) (NNS:[1487..1494] lesions))
            (CC:[1495..1498] and)
            (NP (NN:[1499..1504] lymph) (NNS:[1506..1511] nodes))))
        (PP-MNR (IN:[1512..1514] by)
          (NP
            (ADJP (NN:[1515..1526] methylation) (HYPH:[1526..1527] -)
                  (JJ:[1527..1535] specific))
            (NN:[1536..1539] PCR)))))
    (.:[1539..1540] .)))

;sentence 11 Span:1541..1653
;Sixteen of the 21 (76%) liver metastases  harbored either gene point
;mutations or p16 promoter hypermethylation.
;[1565..1581]:malignancy:"liver metastases"
;[1604..1619]:variation-type:"point mutations"
;[1623..1626]:gene-rna:"p16"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[1541..1548] Sixteen))
      (PP (IN:[1549..1551] of)
        (NP (DT:[1552..1555] the) (CD:[1556..1558] 21)
          (PRN (-LRB-:[1559..1560] -LRB-)
            (NP (CD:[1560..1562] 76) (NN:[1562..1563] %))
            (-RRB-:[1563..1564] -RRB-))
           (NN:[1565..1570] liver) (NNS:[1571..1581] metastases))))
    (VP (VBD:[1583..1591] harbored)
      (NP (CC:[1592..1598] either)
        (NP (NN:[1599..1603] gene)
           (NN:[1604..1609] point) (NNS:[1610..1619] mutations))
        (CC:[1620..1622] or)
        (NP (NN:[1623..1626] p16) (NN:[1627..1635] promoter)
            (NN:[1636..1652] hypermethylation))))
    (.:[1652..1653] .)))

;sentence 12 Span:1654..1966
;Twelve of  the 68 lymph nodes were positive for tumor cells by molecular
;evaluation and  negative for tumor cells by histopathology and cytokeratin
;immunohistochemistry,  whereas none were positive for tumor cells by
;histopathology or negative for  tumor cells by molecular analysis (P =
;0.0005, McNemar's test).
;[1672..1683]...[1702..1713]:malignancy:"lymph nodes"..."tumor cells"
;[1790..1801]:gene-protein:"cytokeratin"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[1654..1660] Twelve))
      (PP (IN:[1661..1663] of)
        (NP (DT:[1665..1668] the) (CD:[1669..1671] 68) (NN:[1672..1677] lymph)
            (NNS:[1678..1683] nodes))))
    (VP (VBD:[1684..1688] were)
      (ADJP-PRD
        (ADJP (JJ:[1689..1697] positive)
          (PP (IN:[1698..1701] for)
            (NP (NN:[1702..1707] tumor) (NNS:[1708..1713] cells)))
          (PP (IN:[1714..1716] by)
            (NP (JJ:[1717..1726] molecular) (NN:[1727..1737] evaluation))))
        (CC:[1738..1741] and)
        (ADJP (JJ:[1743..1751] negative)
          (PP (IN:[1752..1755] for)
            (NP (NN:[1756..1761] tumor) (NNS:[1762..1767] cells)))
          (PP (IN:[1768..1770] by)
            (NP
              (NP (NN:[1771..1785] histopathology))
              (CC:[1786..1789] and)
              (NP (NN:[1790..1801] cytokeratin)
                  (NN:[1802..1822] immunohistochemistry))))))
      (,:[1822..1823] ,)
      (SBAR-ADV (IN:[1825..1832] whereas)
        (S
          (NP-SBJ (NN:[1833..1837] none))
          (VP (VBD:[1838..1842] were)
            (ADJP-PRD
              (ADJP (JJ:[1843..1851] positive)
                (PP (IN:[1852..1855] for)
                  (NP (NN:[1856..1861] tumor) (NNS:[1862..1867] cells)))
                (PP (IN:[1868..1870] by)
                  (NP (NN:[1871..1885] histopathology))))
              (CC:[1886..1888] or)
              (ADJP (JJ:[1889..1897] negative)
                (PP (IN:[1898..1901] for)
                  (NP (NN:[1903..1908] tumor) (NNS:[1909..1914] cells)))
                (PP (IN:[1915..1917] by)
                  (NP (JJ:[1918..1927] molecular) (NN:[1928..1936] analysis)))))
            (PRN (-LRB-:[1937..1938] -LRB-)
              (FRAG
                (S
                  (NP-SBJ (NN:[1938..1939] P))
                  (VP (SYM:[1940..1941] =)
                    (NP (CD:[1942..1948] 0.0005))))
                (,:[1948..1949] ,)
                (NP
                  (NP (NNP:[1950..1957] McNemar) (POS:[1957..1959] 's))
                  (NN:[1960..1964] test)))
              (-RRB-:[1964..1965] -RRB-))))))
    (.:[1965..1966] .)))

;sentence 13 Span:1967..2128
;Moreover, in  three patients with lymph nodes that were histologically
;negative at all sites,  molecular screening detected tumor DNA at one or more
;lymph nodes.
(SENT
  (S
    (ADVP (RB:[1967..1975] Moreover))
    (,:[1975..1976] ,)
    (PP-LOC (IN:[1977..1979] in)
      (NP
        (NP (CD:[1981..1986] three) (NNS:[1987..1995] patients))
        (PP (IN:[1996..2000] with)
          (NP
            (NP (NN:[2001..2006] lymph) (NNS:[2007..2012] nodes))
            (SBAR
              (WHNP-1 (WDT:[2013..2017] that))
              (S
                (NP-SBJ-1 (-NONE-:[2017..2017] *T*))
                (VP (VBD:[2018..2022] were)
                  (NP (RB:[2023..2037] histologically)
                      (JJ:[2038..2046] negative))
                  (PP-LOC (IN:[2047..2049] at)
                    (NP (DT:[2050..2053] all) (NNS:[2054..2059] sites))))))))))
    (,:[2059..2060] ,)
    (NP-SBJ (JJ:[2062..2071] molecular) (NN:[2072..2081] screening))
    (VP (VBD:[2082..2090] detected)
      (NP (NN:[2091..2096] tumor) (NN:[2097..2100] DNA))
      (PP-LOC (IN:[2101..2103] at)
        (NP
          (QP (CD:[2104..2107] one) (CC:[2108..2110] or) (JJR:[2111..2115] more))
          (NN:[2116..2121] lymph) (NNS:[2122..2127] nodes))))
    (.:[2127..2128] .)))

;sentence 14 Span:2129..2348
;Survival  analysis showed a median survival of 1056 days for patients without
;evidence of  lymph node involvement by molecular analysis and 165 days for
;patients with  positive lymph nodes by this approach (P = 0.0005).
;[2297..2317]:malignancy:"positive lymph nodes"
(SENT
  (S
    (NP-SBJ (NN:[2129..2137] Survival) (NN:[2139..2147] analysis))
    (VP (VBD:[2148..2154] showed)
      (NP
        (NP (DT:[2155..2156] a) (NN:[2157..2163] median)
            (NN:[2164..2172] survival))
        (PP (IN:[2173..2175] of)
          (NP
            (NP
              (NP (CD:[2176..2180] 1056) (NNS:[2181..2185] days))
              (PP (IN:[2186..2189] for)
                (NP
                  (NP (NNS:[2190..2198] patients))
                  (PP (IN:[2199..2206] without)
                    (NP
                      (NP (NN:[2207..2215] evidence))
                      (PP (IN:[2216..2218] of)
                        (NP
                          (NP (NN:[2220..2225] lymph) (NN:[2226..2230] node)
                              (NN:[2231..2242] involvement))
                          (PP-LOC (IN:[2243..2245] by)
                            (NP (JJ:[2246..2255] molecular)
                                (NN:[2256..2264] analysis))))))))))
            (CC:[2265..2268] and)
            (NP
              (NP (CD:[2269..2272] 165) (NNS:[2273..2277] days))
              (PP (IN:[2278..2281] for)
                (NP
                  (NP (NNS:[2282..2290] patients))
                  (PP (IN:[2291..2295] with)
                    (NP
                      (NP (JJ:[2297..2305] positive) (NN:[2306..2311] lymph)
                          (NNS:[2312..2317] nodes))
                      (PP (IN:[2318..2320] by)
                        (NP (DT:[2321..2325] this) (NN:[2326..2334] approach)))))))))))
      (PRN (-LRB-:[2335..2336] -LRB-)
        (S
          (NP-SBJ (NN:[2336..2337] P))
          (VP (SYM:[2338..2339] =)
            (NP (CD:[2340..2346] 0.0005))))
        (-RRB-:[2346..2347] -RRB-)))
    (.:[2347..2348] .)))

;sentence 15 Span:2349..2628
;These results indicate that  lymph node metastasis screening in colorectal
;cancer patients by molecular-based  techniques increases the sensitivity of
;tumor cell detection and can be a good  predictor of recurrence in colorectal
;cancer patients with resectable liver  metastases.
;[2378..2399]:malignancy:"lymph node metastasis"
;[2413..2430]:malignancy:"colorectal cancer"
;[2567..2584]:malignancy:"colorectal cancer"
;[2610..2627]:malignancy:"liver  metastases"
(SENT
  (S
    (NP-SBJ (DT:[2349..2354] These) (NNS:[2355..2362] results))
    (VP (VBP:[2363..2371] indicate)
      (SBAR (IN:[2372..2376] that)
        (S
          (NP-SBJ
            (NP
              
              (NML (NN:[2378..2383] lymph) (NN:[2384..2388] node))
              (NN:[2389..2399] metastasis)
              (NN:[2400..2409] screening))
            (PP (IN:[2410..2412] in)
              (NP
                 (JJ:[2413..2423] colorectal) (NN:[2424..2430] cancer)
                (NNS:[2431..2439] patients)))
            (PP (IN:[2440..2442] by)
              (NP
                (ADJP (JJ:[2443..2452] molecular) (HYPH:[2452..2453] -)
                      (VBN:[2453..2458] based))
                (NNS:[2460..2470] techniques))))
          (VP
            (VP (VBZ:[2471..2480] increases)
              (NP
                (NP (DT:[2481..2484] the) (NN:[2485..2496] sensitivity))
                (PP (IN:[2497..2499] of)
                  (NP (NN:[2500..2505] tumor) (NN:[2506..2510] cell)
                      (NN:[2511..2520] detection)))))
            (CC:[2521..2524] and)
            (VP (MD:[2525..2528] can)
              (VP (VB:[2529..2531] be)
                (NP-PRD
                  (NP (DT:[2532..2533] a) (JJ:[2534..2538] good)
                      (NN:[2540..2549] predictor))
                  (PP (IN:[2550..2552] of)
                    (NP
                      (NP (NN:[2553..2563] recurrence))
                      (PP (IN:[2564..2566] in)
                        (NP
                          (NP
                            (NML (JJ:[2567..2577] colorectal)
                                 (NN:[2578..2584] cancer))
                            (NNS:[2585..2593] patients))
                          (PP (IN:[2594..2598] with)
                            (NP (JJ:[2599..2609] resectable)
                               (NN:[2610..2615] liver)
                               (NNS:[2617..2627] metastases))))))))))))))
    (.:[2627..2628] .)))

;section 16 Span:2632..2650
;Publication Types:
(SEC
  (FRAG (NNP:[2632..2643] Publication) (NNP:[2644..2649] Types)
        (::[2649..2650] :)))

;section 17 Span:2652..2666
;Clinical Trial
(SEC
  (FRAG (NNP:[2652..2660] Clinical) (NNP:[2661..2666] Trial)))

;section 18 Span:2668..2685
;Multicenter Study
(SEC
  (FRAG (NNP:[2668..2679] Multicenter) (NNP:[2680..2685] Study)))

;section 19 Span:2689..2734
;PMID: 10499618 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2689..2693] PMID) (::[2693..2694] :) (CD:[2695..2703] 10499618)
        (NN:[2704..2705] -LSB-) (NNP:[2705..2711] PubMed) (::[2712..2713] -)
        (NN:[2714..2721] indexed) (IN:[2722..2725] for)
        (NNP:[2726..2734] MEDLINE-RSB-)))
